From: The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
NCT number | Intervention | Target | Disease setting | Phase | Trial status | Result |
---|---|---|---|---|---|---|
04,149,145 | M4344 + Niraparib | ATRi + PARPi | PARPi-resistant recurrent ovarian cancer | I | Not yet recruiting | / |
04,655,183 | M4344 + Niraparib | ATRi + PARPi | Advanced solid tumors Breast cancer with DDR mutations | I/II | Withdrawn | / |
04,170,153 | M1774 + Niraparib | ATRi + PARPi | Metastatic or locally advanced Unresectable solid tumors | I | Recruiting | / |
02,723,864 | VX-970 + Veliparib + Cisplatin | ATRi + PARPi + Platinum | Refractory solid tumors | I | Completed | 0/3;0/3;2/6;0/7;0/3;3/25;0/6 ORRs in each arms 1/3;2/3;5/6;4/7;3/3;10/25;3/6 DCRs in each arms |
04,267,939 | BAY1895344 + Niraparib | ATRi + PARPi | Advanced solid tumors (excluding prostate cancer) Ovarian cancer | Ib | Recruiting | / |
02,264,678 | AZD6738 + Olaparib | ATRi + PARPi | Advanced solid malignance—H&N SCC, ATM Pro/Def NSCLC, gastric, breast and ovarian cancer | I/II | Recruiting | / |
03,462,342 | AZD6738 + Olaparib | ATRi + PARPi | Recurrent ovarian cancer (platinum-sensitive or platinum-resistant cohort) | II | Recruiting | / |
04,065,269 | AZD6738 + Olaparib | ATRi + PARPi | Relapsed ovarian (fallopian tube/primary peritoneal) and endometrial (uterus) clear cell carcinomas with/without loss of ARID1A expression Other rare relapsed gynecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status | II | Recruiting | / |
03,682,289 | AZD6738 + Olaparib | ATRi + PARPi | Clear cell/metastatic/stage III/IV renal cell carcinoma Locally advanced/metastatic/stage III/IV pancreatic cancer Locally advanced/metastatic malignant solid neoplasm Metastatic urothelial carcinoma | II | Recruiting | / |
04,239,014 | AZD6738 + Olaparib | ATRi + PARPi | Ovarian cancer | II | Withdrawn | / |
04,090,567 | AZD6738 + Olaparib | ATRi + PARPi | Advanced or metastatic breast cancer with germline BRCA1/2 mutations | II | Recruiting | / |
02,937,818 | AZD6738 + Olaparib | ATRi + PARPi | Platinum refractory extensive-stage small-cell lung carcinoma | II | Active, not recruiting | / |
03,787,680 | AZD6738 + Olaparib | ATRi + PARPi | Metastatic castration-resistant prostate cancer (mCRPC) with DNA repair proficiency (DRPro) mCRPC with DNA repair deficiency (DRDef) | II | Active, not recruiting | / |
03,428,607 | AZD6738 + Olaparib | ATRi + PARPi | Relapsed small-cell lung cancer (SCLC) | II | Completed | / |
03,330,847 | AZD6738 + Olaparib AZD1775 + Olaparib | ATRi + PARPi WEE1i + PARPi | Metastatic triple-negative breast cancer(TNBC) with BRC1/2 mutations Metastatic TNBC with other HRR gene mutations other than BRCA1/2 Metastatic TNBC without any mutation of HRR genes | II | Active, not recruiting | / |
02,576,444 | AZD6738 + Olaparib AZD1775 + Olaparib | ATRi + PARPi WEE1i + PARPi | Advanced solid tumors with mutations in homologous—DNA repair (HDR) genes or mutations such as ATM, CHK2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC Advanced solid tumors with mutations of TP53 or KRAS gene | II | Active, Not Recruiting | / |
03,057,145 | Prexasertib + Olaparib | CHK1i + PARPi | Advanced solid tumors | I | Completed | / |
02,511,795 | AZD1775 + Olaparib | WEE1i + PARPi | Refractory solid tumors Relapsed small-cell lung cancer (SCLC) | Ib | Completed | 11.1% ORR in the total polulation; 55.7% DCR in the total population |
03,579,316 | AZD1775 + Olaparib | WEE1i + PARPi | PARPi-resistant recurrent ovarian (fallopian tube/primary peritoneal) cancers | II | Recruiting | / |